AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse events. SUZHOU, China, May 29, 2025 /PRNewswire/ -- AccurEdit Therapeutics today...
AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy
SUZHOU, China, May 12, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy...
AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001,...